Skip to main content
OpenTrials
Completed

NCT Number: NCT00477594

Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia

The purpose of this study is to evaluate the safety and efficacy of extended dosing of mipomersen in patients with familial hypercholesterolemia on lipid-lowering therapy who have completed either the 301012-CS8 (NCT00280995) or 301012-CS9 (NCT00281008) clinical drug trials.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lipid Metabolism, Inborn Errors Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dyslipidemias Genetic Diseases, Inborn Homozygous Familial Hypercholesterolemia Hypercholesterolemia Hypercholesterolemia, Autosomal Dominant Hyperlipidemias Hyperlipoproteinemia Type II Hyperlipoproteinemias Infant, Newborn, Diseases Lipid Metabolism Disorders Metabolic Diseases Metabolic Disorder Metabolism, Inborn Errors Nutritional and Metabolic Diseases

Age range

12 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Chicago, Illinois, United States

Loading trial locations.

About this study

Familial Hypercholesterolemia (FH) is an autosomal dominant metabolic disorder characterized by markedly elevated low density lipoprotein (LDL), premature onset of atherosclerosis, and development of xanthomata. There are two distinct subpopulations that have a high unmet medical need due to the lack of alternative therapy: homozygotes, who have two defective LDL receptor (LDL-R) genes, and heterozygotes with a history of cardiovascular disease (CVD) on maximally tolerated therapy. Treatment for FH is directed at lowering plasma levels of LDL-C.

Mipomersen is an antisense drug targeted to human apolipoprotein B (apoB), the principal apolipoprotein of atherogenic LDL-C and its metabolic precursor, very low density lipoprotein (VLDL). Mipomersen is complimentary to the coding region of the messenger ribonucleic acid (mRNA) for apo-B. Inhibition of apo-B would be expected to impair VLDL synthesis and result in lowered levels of LDL-C.

In early clinical trials, mipomersen has been shown to reduce levels of LDL-C to recommended target levels in some participants.

This was an open-label extension study, which consisted of a ≤2-week screening period, up to 3 years of treatment with mipomersen, and a 24-week post-treatment follow-up period. Patients who participated in Cohorts A, B, or C in study 301012-CS9 were randomized in a 1:1 ratio to mipomersen 200 mg once a week (QW) or 200 mg mipomersen every other week (QOW) for up to 3 years. Patients randomized to mipomersen 200 mg QOW were allowed to receive mipomersen 200 mg QW at the Investigator's discretion after the first 52 weeks of the treatment period. Patients who participated in study 301012-CS8 or Cohort D of study 301012-CS9 received 200 mg mipomersen QW for up to 3 years.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Satisfactory completion of dosing and Week 7 or Week 15 assessments (depending on the treatment and dose received) in their initial study (Protocol 301012-CS8 (NCT00280995) or 301012-CS9 (NCT00281008)).

Exclusion criteria

  • Have a new condition or worsening of existing condition which in the opinion of the Investigator would make the patient unsuitable for enrollment, or could interfere with patient's participation in or completion of the study.

Treatment and study plan

mipomersen sodium

Drug

200 mg/ml, in 1 ml solution for subcutaneous injection.

Other names: ISIS 301012, Kynamro™

Primary outcomes

  1. Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)

    Time frame: Baseline and Weeks 52 and 104

    LDL cholesterol was measured in mg/dL. Samples were taken following an overnight fast. For patients with triglycerides <400 mg/dL, LDL-C was obtained using Friedewald's calculation; and for patients with triglycerides ≥400 mg/dL, LDL-C was directly measured by the central laboratory using ultracentrifugation. For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.

  2. Low-density Lipoprotein Cholesterol (LDL-C) Over Time

    Time frame: Baseline and Weeks 52 and 104.

    Samples were taken following an overnight fast. For patients with triglycerides <400 mg/dL, LDL-C was obtained using Friedewald's calculation; and for patients with triglycerides ≥400 mg/dL, LDL-C was directly measured by the central laboratory using ultracentrifugation. For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.

Secondary outcomes

  1. Percent Change From Baseline in Apolipoprotein B

    Time frame: Baseline and Weeks 52 and 104

    Apolipoprotein B was measured in mg/dL. Samples were taken following an overnight fast. For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.

  2. Apolipoprotein B Over Time

    Time frame: Baseline and Weeks 52 and 104.

    For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.

  3. Percent Change From Baseline in Total Cholesterol

    Time frame: Baseline and Weeks 52 and 104.

    Total cholesterol was measured in mg/dL. Samples were taken following an overnight fast.

  4. Total Cholesterol Over Time

    Time frame: Baseline and Weeks 52 and 104.

    For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.

  5. Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol

    Time frame: Baseline and Weeks 52 and 104.

    Non-high-density lipoprotein cholesterol was measured in mg/dL. Samples were taken following an overnight fast.

  6. Non-High-Density Lipoprotein Cholesterol Over Time

    Time frame: Baseline and Weeks 52 and 104.

    For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.

  7. Number of Participants With Treatment-Emergent Adverse Events (AEs)

    Time frame: 2 years

    AEs were considered as related if assessed by the Investigator as possibly, probably or definitely related to study drug. The severity of each event was assessed using the following categories: Mild (symptom(s) barely noticeable to the patient or do not make the patient uncomfortable); Moderate (symptom(s) of a sufficient severity to make the patient uncomfortable, performance of daily activities is influenced) or Severe (symptom(s) of a sufficient severity to cause the patient severe discomfort, may cause cessation of treatment with the study drug). Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above.

  8. Percent Change From Baseline in Clinical Chemistry Parameters

    Time frame: Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.

  9. Percent Change From Baseline in Hematology Parameters

    Time frame: Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment

  10. Percent Change From Baseline in Blood Pressure

    Time frame: Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.

  11. Percent Change From Baseline in Pulse Rate

    Time frame: Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.

  12. Percent Change From Baseline in Respiratory Rate

    Time frame: Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.

Other outcomes

  1. Percent Change From Baseline in Triglycerides

    Time frame: Baseline and Weeks 52 and 104.

    Triglycerides were measured in mg/dL. Samples were taken following an overnight fast.

  2. Triglycerides Over Time

    Time frame: Baseline and Weeks 52 and 104.

    For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.

  3. Percent Change From Baseline in Lipoprotein(a)

    Time frame: Baseline and Weeks 52 and 104.

    Lipoprotein(a) was measured in mg/dL. Samples were taken following an overnight fast.

  4. Lipoprotein(a) Over Time

    Time frame: Baseline and Weeks 52 and 104.

    For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.

  5. Percent Change From Baseline in Very-Low-Density Lipoprotein (VLDL) Cholesterol

    Time frame: Baseline and Weeks 52 and 104.

    Very-Low-Density Lipoprotein (VLDL) Cholesterol was measured in mg/dL. Samples were taken following an overnight fast.

  6. Very-Low-Density Lipoprotein (VLDL) Cholesterol Over Time

    Time frame: Baseline and Weeks 52 and 104.

    For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.

  7. Percent Change From Baseline in Ratio of Low-density Lipoprotein Cholesterol to High-density Lipoprotein Cholesterol

    Time frame: Baseline and Weeks 52 and 104.

  8. Ratio of Low-density Lipoprotein Cholesterol to High-density Lipoprotein Cholesterol Over Time

    Time frame: Baseline and Weeks 52 and 104.

    For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.

  9. Percent Change From Baseline in Apolipoprotein A1

    Time frame: Baseline and Weeks 52 and 104.

    Apolipoprotein A1 was measured in mg/dL. Samples were taken following an overnight fast.

  10. Apolipoprotein A1 Over Time

    Time frame: Baseline and Weeks 52 and 104.

    For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.

  11. Percent Change From Baseline in High-Density Lipoprotein Cholesterol

    Time frame: Baseline and Weeks 52 and 104.

    High-Density Lipoprotein (HDL) Cholesterol was measured in mg/dL. Samples were taken following an overnight fast.

  12. High-Density Lipoprotein Cholesterol Over Time

    Time frame: Baseline and Weeks 52 and 104.

    For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study. For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.

Sponsors and collaborators

Lead sponsor

Kastle Therapeutics, LLC

Industry

Collaborators

  • Ionis Pharmaceuticals, Inc.

Registry information

Official study title

An Open-Label Extension Study to Assess the Long-term Safety and Efficacy of Mipomersen in Subjects With Familial Hypercholesterolemia

Important dates

Study start
2007
Primary completion
2011
Study completion
2011
First posted
May 24, 2007
Registry last updated
Sep 9, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.